update, read between the lines
Asia Cannabis name change to Asia Green Biotechnology
2020-04-15 15:47 ET - Change Name
CSE bulletin 2020-0418
Asia Cannabis Corp. will change its name to Asia Green Biotechnology Corp.
The shares will begin trading under the new name on April 16, 2020.
The symbol will remain as ASIA.
Disclosure documents are available on the Canadian Securities Exchange website.
Effective date: April 16, 2020
Symbol: ASIA CANNABIS CORP. CONFIRMS PATENT APPLICATION FILED BY SWYSH INC. IN RELATION TO ANTI-VIRAL TREATMENTS
Asia Cannabis Corp. has provided the following corporate developments.
Asia Cannabis has previously announced that it had entered into an agreement with Swysh Inc., an Alberta research and development company focused on specific cannabinoid-based research and that owns proprietary technology and related intellectual property aimed at providing the basis for creation of systemic and topical treatments for a variety of external and internal conditions and ailments, including a number of anti-viral and preventive health care applications. This agreement grants a licence to Asia Cannabis to deploy the technology for the purpose of completing further research, development, testing, and additional validation and establishment of practical applications with a view to commercialization of the technology in the greater region of Asia.
Today, the company and Swysh confirm that a patent application has been filed by agents for Swysh with the U.S. Patent Office in respect of new and unique cannabis sativa lines, extracts and methods for their use to inhibit the levels of ACE2 receptor in oral, lung and intestinal epithelial tissues to prevent entry of SARS-CoV-2 and related viruses, to treat the cytokine storm that precedes and underlies acute respiratory distress syndrome in COVID-19 and other diseases, and to affect viral life cycle processes. Extracts of novel hemp lines can be combined with anti-viral agents and anti-inflammatory extracts of turmeric, chamomile, sage, fennel, ginger, rosehip or other herbs, as well as probiotics, to increase their efficacy.
Dr. Igor Kovalchuk, a director of Asia Cannabis and the chief executive officer, director and controlling shareholder of Swysh, stated: "Swysh has been actively researching and developing the protocols associated with the creation of these new cannabis sativa lines, extracts and their related applications for some time. It is extremely serendipitous and fortunate that we have been able to make these advances relative to specialized viral treatments at a time when a significant outbreak occurs such as what we see in the COVID-19 crisis. We are actively and aggressively moving ahead with further research, and next steps include substantiation of our findings through additional molecular research, including cell lines and viral replicons, as well as preparation and submission of application for conducting clinical trials. Through its licence agreement with Swysh, we believe ACC will be in a position to provide key assistance in validating these treatments by utilizing the resources and skills of its academic and business partners in the Asian region."
About Asia Cannabis Corp.
Asia Cannabis is an early-stage international agritechnology company focused on the development, evaluation, testing, application and, ultimately, supply to the market of proprietary organic hybridization technology and certain products derived from that technology. The core approach of the business is centred on the planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of licence agreements with InPlanta Biotechnologies Inc. and Swysh.
In conjunction with both InPlanta and Swysh, the company is developing varieties of hemp with superior growth and production characteristics in the various environments found in the licensed territories. With the data and associated knowledge gained from these activities, the company intends to leverage the technology to develop a portfolio of strategic hemp investments to take advantage of both the changing social climate relative to hemp use and the historical acceptance of the use of these products and their derivatives in certain of the jurisdictions granted under the licence agreements.
We seek Safe Harbor.